FDA Approves New CardioMEMS HF Capabilities to Boost Patient Engagement
ABT sits 19% above its 52-week low of $81.97.
Summary
Abbott received FDA approval for new capabilities on its CardioMEMS HF System that help patients engage in their heart condition care. This expands the device's functionality and strengthens Abbott's heart failure portfolio. The approval follows a series of recent FDA wins for Abbott, including SimpleScreen CRC, Libre Duo 10 Day, and TactiFlex Duo. It reinforces Abbott's position in connected health and remote monitoring, a key growth area. No financial terms were disclosed, but the approval is a positive regulatory milestone.
At the time of this announcement, ABT was trading at $97.53 on NYSE in the Life Sciences sector, with a market capitalization of approximately $168.7B. The 52-week trading range was $81.97 to $135.37. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.